Leslie Trigg Sells 14,611 Shares of Outset Medical, Inc. (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 14,611 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $0.90, for a total value of $13,149.90. Following the completion of the transaction, the chief executive officer now owns 880,969 shares of the company’s stock, valued at $792,872.10. The trade was a 1.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 21st, Leslie Trigg sold 65,236 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total value of $52,188.80.
• On Monday, January 13th, Leslie Trigg sold 33,227 shares of Outset Medical stock. The stock was sold at an average price of $0.81, for a total value of $26,913.87.
• On Tuesday, January 7th, Leslie Trigg sold 10,227 shares of Outset Medical stock. The stock was sold at an average price of $1.29, for a total value of $13,192.83.

Outset Medical Stock Performance

Shares of OM stock opened at $0.96 on Friday. Outset Medical, Inc. has a fifty-two week low of $0.44 and a fifty-two week high of $5.22. The business has a fifty day simple moving average of $0.95 and a 200-day simple moving average of $0.85. The company has a debt-to-equity ratio of 4.12, a quick ratio of 5.04 and a current ratio of 6.49.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). Outset Medical had a negative net margin of 112.57% and a negative return on equity of 175.64%. The firm had revenue of $29.47 million during the quarter, compared to analysts’ expectations of $28.47 million. On average, analysts predict that Outset Medical, Inc. will post -1.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research report on Tuesday, January 7th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OM. National Bank of Canada FI increased its position in shares of Outset Medical by 79.2% in the third quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock valued at $35,000 after buying an additional 23,164 shares in the last quarter. Huntington National Bank increased its position in shares of Outset Medical by 46.2% in the third quarter. Huntington National Bank now owns 63,306 shares of the company’s stock valued at $43,000 after buying an additional 20,000 shares in the last quarter. Two Sigma Securities LLC increased its position in shares of Outset Medical by 190.0% in the fourth quarter. Two Sigma Securities LLC now owns 42,477 shares of the company’s stock valued at $47,000 after buying an additional 27,830 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Outset Medical during the fourth quarter valued at $50,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Outset Medical during the fourth quarter valued at $174,000.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.